Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Fosun Bets $60 Million on Late-Stage Alzheimer's Drug

Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Editorial illustration

Summary

Pharmaceutical company Fosun Pharma is making a major financial bet on a potential new treatment for Alzheimer's disease. The company has paid $60 million to secure an option on a medical program developed by AriBio. Instead of buying the drug outright, an option agreement gives Fosun the right to expand its ownership later if the drug performs well.

AriBio's treatment is currently in Phase 3 development. This is the final and most crucial stage of clinical testing in humans, designed to prove whether a medicine is truly safe and effective before it can be submitted to regulators for approval. If the ongoing research yields promising results, Fosun has the opportunity to pay an additional $80 million to expand its rights to the medical asset.

However, the drug is not at the finish line just yet. Because the treatment is still undergoing testing, its clinical success is not yet confirmed. The cautious structure of the deal reflects this uncertainty. By purchasing an option rather than making a full acquisition, Fosun is managing its financial risk while keeping a foot in the door.

Why it matters.

Developing new medicines for Alzheimer's disease is notoriously challenging and requires massive financial investments. This $60 million initial payment, with the potential for another $80 million, highlights how pharmaceutical companies structure deals to balance high potential rewards with significant scientific risks.

If the Phase 3 trials are successful, this financial backing could help push a new Alzheimer's therapy closer to the market. Still, the cautious nature of the option agreement serves as a clear reminder that final regulatory approval is never guaranteed until the data proves the drug is effective.

From the source

The story in numbers.

Initial option payment
$60 million
Additional payment for expanded rights
$80 million
Clinical trial stage
Phase 3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Fosun Bets $60 Million on Late-Stage Alzheimer's Drug — Daily Strand